References
- Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187-193.
- Celia D, Wagner L, Cashy J, Hensing TA, Yount S, Lilenbaum RC. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. J Natl Cancer Inst Monogr 2007:53-60.
- Sloan JA, Celia D, Frost M, Guyatt GH, Sprangers M, Symonds T. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 2002;77:367-370.
- Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-smaU-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
- Celia DF. Measuring quality of life in palliative care. Semin Oncol 1995;22:73-81.
- Aaronson NK Quality of life: what is it? How should it be measured? Oncology (Williston Park) 1988;2:69-76, 64.
- Celia D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007;45:S3-S11.
- Deandrea S, Montanari M, Moja L, ApoIone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008;19:1985-1991.
- Billings JA What is palliative care? J Palliat Med 1998;1:73-81.
- Ellison NM. Regulatory issues for prescribing schedule II opioids at the end of life #198. J Palliat Med 2010;13:605-606.
- Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 2003;25:559-577.